INBX
Inhibrx Biosciences Inc.
$87.39
-1.68
(-1.89%)
Mkt Cap
1.28B
Volume
271,691
52W Range
20.55-155.29
Sector
Healthcare
Beta
3.43
EPS (TTM)
-8.39
P/E Ratio
-8.74
Revenue (TTM)
1.30M
Rev Growth (5Y)
-36.7%
EPS Growth (5Y)
N/A
Company Description
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30M | 200,000 | 1.80M | 2.19M | 7.12M | 12.81M | 9.09M | 7.50M | 7.95M | 6.67M |
| Net Income | (140.06M) | 1.69B | (241.36M) | (145.23M) | (81.77M) | (75.64M) | (51.40M) | (31.16M) | (19.44M) | (8.27M) |
| EPS | -9.04 | 116.58 | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 | -0.68 | -0.23 |
| Free Cash Flow | (129.82M) | (197.01M) | (197.90M) | (115.99M) | (81.19M) | (49.33M) | (33.89M) | (24.52M) | (20.09M) | (18.32M) |
| FCF / Share | -8.38 | -13.61 | -4.20 | -2.89 | -2.14 | -1.95 | -0.93 | -0.91 | -0.70 | -0.50 |
| Operating CF | (129.79M) | (194.41M) | (193.31M) | (115.30M) | (80.32M) | (47.97M) | (32.08M) | (23.09M) | (18.75M) | (18.11M) |
| Total Assets | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M | 143.74M | 26.49M | 9.98M | 17.25M | 21.27M |
| Total Debt | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M | 37.45M | 41.73M | 9.49M | 14.66M | 18.92M |
| Cash & Equiv | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M | 128.66M | 11.54M | 2.10M | 13.47M | 20.02M |
| Book Value | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M | 75.47M | (93.57M) | (57.64M) | (28.77M) | (9.25M) |
| Return on Equity | -17.52 | 12.63 | -5.55 | -2.50 | -1.56 | -1.00 | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1.30M | 0 | 100,000 | 0 | 100,000 | 0 | 1.63M | 119,000 | 30,000 |
| Net Income | (33.44M) | (32.83M) | (35.26M) | (28.65M) | (43.31M) | (47.87M) | (43.86M) | 1.86B | (78.71M) | (93.60M) | (51.79M) | (47.05M) |
| EPS | -2.15 | -2.11 | -2.28 | -1.85 | -2.80 | -3.31 | -2.84 | 128.35 | -1.44 | -1.73 | -1.10 | -1.08 |
| Free Cash Flow | (38.03M) | (30.12M) | (33.83M) | (29.95M) | (35.92M) | (43.74M) | (30.53M) | (58.57M) | (64.17M) | (60.26M) | (55.06M) | (42.62M) |
| FCF / Share | -2.44 | -1.94 | -2.19 | -1.94 | -2.32 | -3.02 | -1.97 | -4.05 | -1.18 | -1.12 | -1.17 | -0.98 |
| Operating CF | (38.03M) | (30.12M) | (33.82M) | (29.95M) | (35.90M) | (43.72M) | (30.28M) | (57.36M) | (63.05M) | (56.82M) | (54.24M) | (42.30M) |
| Total Assets | 183.97M | 146.48M | 177.47M | 212.12M | 242.64M | 180.77M | 222.56M | 258.42M | 288.58M | 307.89M | 372.73M | 213.17M |
| Total Debt | 5.90M | 107.01M | 6.99M | 106.79M | 106.53M | 8.05M | 1.83M | 2.17M | 210.89M | 210.14M | 207.37M | 208.61M |
| Cash & Equiv | 161.66M | 124.22M | 153.09M | 186.57M | 216.52M | 152.60M | 196.33M | 226.86M | 252.48M | 277.92M | 337.33M | 192.49M |
| Book Value | (21.04M) | 7.99M | 36.83M | 68.56M | 94.44M | 133.58M | 178.47M | 219.37M | 11.57M | 43.50M | 129.59M | (24.81M) |
| Return on Equity | N/A | -4.11 | -0.96 | -0.42 | -0.46 | -0.36 | -0.25 | 8.47 | -6.80 | -2.15 | -0.40 | N/A |
INBX News
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study